Techulon to Introduce Glycofect Drug Delivery Reagent to Northern Virginia/Maryland Corridor

Techulon, which specialises in the delivery of low-toxic genes has announced that it plans to expand its reach to the Northern Virginia/Maryland corridor by providing customer access and support to its Glycofect transfection reagent.

As part of its expansion plans, the company will educate customers about its Glycofect platform through various events and seminars and train cell researchers to increase their usage of Glycofect in research programs involving dermal fibroblasts, aortic smooth muscle cells and cortical and Glioma neurons.

The company will be the core participant in the NIH Research Festival to be held in October and will also conduct luncheon workshops throughout the year, 2012. Mr. Bill McKay from Olney Biosciences will be the coordinator and the key account manager who will serve major clients such as John Hopkins University, National Cancer Institute and National Institutes of Health. According to Frank Akers, who is the President of Techulon the awareness of Glycofect is encouraging researchers to use the platform in various important cell research programs and the company will also focus on creating more awareness among customers and the general research community. Glycofect is a transfection agent for polymeric nanoparticle delivery and is specifically designed for use on primary cells that can be used for treatment. The platform is currently being used by laboratories in corporate, governments and universities across 20 countries.